Literature DB >> 4044036

Purification and vaccine potential of Klebsiella capsular polysaccharides.

S J Cryz, E Fürer, R Germanier.   

Abstract

Capsular polysaccharide (CPS) from 18 Klebsiella strains of different capsular types was isolated and characterized. Purified CPSs were composed primarily of carbohydrate with trace quantities of protein, nucleic acids, and lipopolysaccharide. All CPSs were of a high molecular weight, possessing a Kd of 0.01 to 0.11 as determined by gel filtration over Sepharose CL-4B. Low levels of lipopolysaccharide present in all preparations were responsible for the highly pyrogenic nature of one-half of the CPS preparations. Treatment of capsular material with dilute NaOH in 95% ethanol markedly reduced the pyrogenicity of all preparations and had a negligible effect on their molecular weight. The immunogenicity of the various native CPSs for mice varied considerably from serotype to serotype, but all evoked an anticapsular immunoglobulin G response. Five of 18 NaOH-treated polysaccharides were significantly (P less than 0.05) less immunogenic than their native counterparts. Human immunoglobulin G prepared from volunteers immunized with either native or NaOH-treated KP1-0 capsular polysaccharide was equally effective at preventing experimental fatal Klebsiella pneumoniae burn wound sepsis in mice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044036      PMCID: PMC262160          DOI: 10.1128/iai.50.1.225-230.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Studies on immunological paralysis. V. The influence of molecular weight on the immunogenicity, tolerogenicity and antibody-neutralizing activity of the 3 pneumococcal polysaccharide.

Authors:  J G Howard; H Zola; G H Christie; B M Courtenay
Journal:  Immunology       Date:  1971-09       Impact factor: 7.397

2.  [Isolation and qualitative component analysis of Klebsiella K-antigens].

Authors:  W Nimmich
Journal:  Z Med Mikrobiol Immunol       Date:  1968

3.  Standardization and control of meningococcal vaccines, group A and group C polysaccharides.

Authors:  K H Wong; O Barrera; A Sutton; J May; D H Hochstein; J D Robbins; J B Robbins; P D Parkman; E B Seligmann
Journal:  J Biol Stand       Date:  1977

4.  Nosocomial pneumonia. A continuing major problem.

Authors:  J R Graybill; L W Marshall; P Charache; C K Wallace; V B Melvin
Journal:  Am Rev Respir Dis       Date:  1973-11

5.  Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases.

Authors:  J E McGowan; M W Barnes; M Finland
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

6.  Quantitative determination of the human immune response to immunization with meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; R Triau; K J Sparks
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

7.  Klebsiella bacteremia.

Authors:  J Z Montgomerie; J K Ota
Journal:  Arch Intern Med       Date:  1980-04

8.  Sequential outbreaks of infection due to Klebsiella pneumoniae in a neonatal intensive care unit: implication of a conjugative R plasmid.

Authors:  S M Markowitz; J M Veazey; F L Macrina; C G Mayhall; V A Lamb
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

9.  Nosocomial infections in the immunocompromised adult.

Authors:  L S Young
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

10.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  20 in total

1.  Immunogenic properties of Klebsiella pneumoniae type 2 capsular polysaccharide.

Authors:  A Robert; H Jouin; J M Fournier
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

2.  O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections.

Authors:  M Trautmann; M Ruhnke; T Rukavina; T K Held; A S Cross; R Marre; C Whitfield
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

3.  A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Peter H Seeberger; Claney L Pereira; Naeem Khan; Guozhi Xiao; Elizabeth Diago-Navarro; Katrin Reppe; Bastian Opitz; Bettina C Fries; Martin Witzenrath
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-05       Impact factor: 15.336

4.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

5.  Immunization against fatal experimental Klebsiella pneumoniae pneumonia.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

6.  Genetic exchange of determinants for capsular polysaccharide biosynthesis between Klebsiella pneumoniae strains expressing serotypes K2 and K21a.

Authors:  I Ofek; K Kabha; A Athamna; G Frankel; D J Wozniak; D L Hasty; D E Ohman
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Molecular serotyping of Klebsiella species isolates by restriction of the amplified capsular antigen gene cluster.

Authors:  Sylvain Brisse; Sylvie Issenhuth-Jeanjean; Patrick A D Grimont
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

8.  Purification and partial characterization of the capsular polymer of Haemophilus pleuropneumoniae serotype 5.

Authors:  T J Inzana
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

9.  Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans.

Authors:  M Granström; B Wretlind; B Markman; S Cryz
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

10.  Immunogenicity of Vibrio vulnificus capsular polysaccharides and polysaccharide-protein conjugates.

Authors:  J G Simonson; R J Siebeling
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.